<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03427086</url>
  </required_header>
  <id_info>
    <org_study_id>BIO-2017-0270</org_study_id>
    <nct_id>NCT03427086</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of High Dose Biotin in Patients With Amyotrophic Lateral Sclerosis</brief_title>
  <official_title>Safety and Tolerability of High Dose Biotin in Patients With Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American University of Beirut Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>American University of Beirut Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized double blinded randomized 2:1 study. The duration of the study is 6
      month. The safety and tolerability of high doses of biotin (300 mg/ day) will be compared to
      placebo in patients with amyotrophic lateral sclerosis. Patients will be evaluated at
      baseline, 3, and 6 month. The primary outcome will be any adverse effects recorded. The
      secondary outcomes will be motor disability measured by ALS-FRS, change in Pulmonary function
      test parameters (FEV1- FVC), change in subject weight (in kg).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 29, 2018</start_date>
  <completion_date type="Anticipated">December 10, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 10, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, double blind, placebo control, randomized 2:1 study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The subjects, care givers, investigator, and coordinator will be blinded. The pharmacist, who will be responsible for the drug supply, will be unblinded. The investigational drug and the placebo will have identical pill shape and color. They will be supplied in identical boxes.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>6 months</time_frame>
    <description>Any adverse effects resulting from receiving high dose biotin in patients with amyotrophic lateral sclerosis will be recorded</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Motor disability measurement</measure>
    <time_frame>6 months</time_frame>
    <description>The motor disability will be measured in the both arms using the revised amyotrophic lateral sclerosis functional rating scale (ALS-FRSr). This scale measures the progression and the severity of the disease. It is compose of 12 questions, each questions can have a score from 0 to 4. Questions 1 to 3 are related to bulbar onset, questions 4 to 9 are related to limb onset and questions 10-12 are related to respiratory onset. The minimum score is 0 and the maximum total score is 48. The higher the score the better the functional status. The lower the score the worse the functional status of the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulmonary function test parameters ( FEV1- FVC)</measure>
    <time_frame>6 months</time_frame>
    <description>Forced expiratory volume in 1 second (FEV1) measured in percents and forced vital capacity (FVC) measured in liters will be measured in the both study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight changes</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in body weight (in kilograms) will be measured in both study arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Interventional</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will received high dose of biotin (300 mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biotin</intervention_name>
    <description>High dose biotin</description>
    <arm_group_label>Interventional</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo tablet similar in shape and size to the biotin tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Amyotrophic Lateral Sclerosis (ALS) volunteers must be diagnosed within 3 years prior
             to participation as having possible, probable, or definite ALS, either sporadic or
             familial according to modified El Escorial criteria

          -  Age 18-80, able to provide informed consent, and comply with study procedures

          -  Participants must not have started Riluzole and/or Nuedexta for at least 30 days, or
             be on a stable dose of Riluzole and/or Nuedexta for at least 30 days, prior to
             screening (Riluzole and/or Nuedexta -naïve participants are permitted in the study)

        Exclusion Criteria:

          -  The presence of unstable psychiatric disease, cognitive impairment, or dementia that
             would impair ability of the participant to provide informed consent, according to PI
             judgment.

          -  Exposure to any experimental agent within 30 days of entry or at any time during the
             trial or enrollment in another research study within 30 days of or during this trial.

          -  Slow Vital Capacity test less than 50% of the predicted value Patients who had already
             undergone tracheostomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Achraf Makki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>American University of Beirut Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>American univeristy of Beirut medical center</name>
      <address>
        <city>Beirut</city>
        <zip>1107 2020</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/books/NBK20413/</url>
    <description>Circulation and Energy Metabolism of the Brain</description>
  </link>
  <reference>
    <citation>Kawamata H, Manfredi G. Mitochondrial dysfunction and intracellular calcium dysregulation in ALS. Mech Ageing Dev. 2010 Jul-Aug;131(7-8):517-26. doi: 10.1016/j.mad.2010.05.003. Epub 2010 May 20. Review.</citation>
    <PMID>20493207</PMID>
  </reference>
  <results_reference>
    <citation>Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009 Feb 3;4:3. doi: 10.1186/1750-1172-4-3. Review.</citation>
    <PMID>19192301</PMID>
  </results_reference>
  <results_reference>
    <citation>Musarò A. Understanding ALS: new therapeutic approaches. FEBS J. 2013 Sep;280(17):4315-22. doi: 10.1111/febs.12087. Epub 2013 Jan 3. Review.</citation>
    <PMID>23217177</PMID>
  </results_reference>
  <results_reference>
    <citation>Zimmermann KC, Bonzon C, Green DR. The machinery of programmed cell death. Pharmacol Ther. 2001 Oct;92(1):57-70. Review.</citation>
    <PMID>11750036</PMID>
  </results_reference>
  <results_reference>
    <citation>Celsi F, Pizzo P, Brini M, Leo S, Fotino C, Pinton P, Rizzuto R. Mitochondria, calcium and cell death: a deadly triad in neurodegeneration. Biochim Biophys Acta. 2009 May;1787(5):335-44. doi: 10.1016/j.bbabio.2009.02.021. Epub 2009 Mar 4. Review.</citation>
    <PMID>19268425</PMID>
  </results_reference>
  <results_reference>
    <citation>Atamna H, Newberry J, Erlitzki R, Schultz CS, Ames BN. Biotin deficiency inhibits heme synthesis and impairs mitochondria in human lung fibroblasts. J Nutr. 2007 Jan;137(1):25-30.</citation>
    <PMID>17182796</PMID>
  </results_reference>
  <results_reference>
    <citation>Stys PK, Zamponi GW, van Minnen J, Geurts JJ. Will the real multiple sclerosis please stand up? Nat Rev Neurosci. 2012 Jun 20;13(7):507-14. doi: 10.1038/nrn3275. Review. Erratum in: Nat Rev Neurosci. 2012 Aug;13(8):597.</citation>
    <PMID>22714021</PMID>
  </results_reference>
  <results_reference>
    <citation>Luessi F, Siffrin V, Zipp F. Neurodegeneration in multiple sclerosis: novel treatment strategies. Expert Rev Neurother. 2012 Sep;12(9):1061-76; quiz 1077. doi: 10.1586/ern.12.59. Review.</citation>
    <PMID>23039386</PMID>
  </results_reference>
  <results_reference>
    <citation>Sedel F, Papeix C, Bellanger A, Touitou V, Lebrun-Frenay C, Galanaud D, Gout O, Lyon-Caen O, Tourbah A. High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mult Scler Relat Disord. 2015 Mar;4(2):159-69. doi: 10.1016/j.msard.2015.01.005. Epub 2015 Jan 24.</citation>
    <PMID>25787192</PMID>
  </results_reference>
  <results_reference>
    <citation>Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, De Sèze J, Debouverie M, Gout O, Clavelou P, Defer G, Laplaud DA, Moreau T, Labauge P, Brochet B, Sedel F, Pelletier J; MS-SPI study group. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. Mult Scler. 2016 Nov;22(13):1719-1731. Epub 2016 Sep 1.</citation>
    <PMID>27589059</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2018</study_first_submitted>
  <study_first_submitted_qc>February 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2018</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>American University of Beirut Medical Center</investigator_affiliation>
    <investigator_full_name>Johnny Salameh</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Amyotrophic lateral sclerosis</keyword>
  <keyword>Biotin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biotin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

